DiabetesLab: We treat diabetes as a mathematical problem.
Financial Sustainability Plan: What is this solution’s plan to ensure financial sustainability?
Marketplace: Who else is addressing the problem outlined here? How does the proposed project differ from these approaches?
Founding Story
Team
Boehringer Ingelheim will have an opportunity to (a) co-create impact for people living with type 1 diabetes and raise awareness for diabetes in general, to prevent complications, and (b) collaborate with DiabetesLab on technological solutions to enhance Boehringer Ingelheim's existing offerings for people living with type 2 diabetes. We use technological innovation to help people achieve HbA1c<7% to minimize complications and reduce treatment costs (nowadays the majority of patients worldwide do not achieve this target). Business model that we consider: freemium for end users; B2B with reducing costs for insurance companies and healthcare providers; B2B with providing additional value to existing offerings.
Distribution Channels, Relationships/New Contacts, Marketing/Communications Support, Public Policy Knowledge, Access to Capital.
Mentoring and coaching in running the healthcare-related business and reaching B2B customers in pharmaceutical industry, medical device industry, insurance companies and healthcare providers. Networking and access to the leading players in diabetes market. Guidance and support on regulatory pathways.
Deep understanding of an unmet need in a specific market/context, Other.
Improving the affordability of healthcare (e.g., microinsurance, reducing the economic cost of care), Remote care solutions for health management, treatment, and diagnosis, Packaging of health products and services to address needs currently unmet.
Technological tools (such as a mobile app or a web app) that would use DiabetesLab's data-driven technology to support and enhance Boehringer Ingelheim's existing solutions for type 2 diabetes and type 1 diabetes.
a new product.
Using technology to enhance value proposition of existing diabetes medications.
We use technological innovation to help people achieve HbA1c<7% to minimize complications and reduce treatment costs (nowadays the majority of patients worldwide do not achieve this target). This project aims to achieve the same goals: enhancing existing medical solutions to help patients achieve better results in their treatment.
Diabetes is one of the core focus areas of BI.
My organization would contribute:
- Technological expertise: creation of data-driven solutions for diabetes powered with artificial intelligence; expertise in creation of web pages, mobile apps and web apps.
- Field expertise: knowledge of diabetes, related technology and unmet needs of the patients, knowledge of best practises to enhance patient engagement.
Boehringer Ingelheim would contribute:
- Medical, market and business expertise:
- specific expertise and data related to BI's medications for type 2 diabetes and type 1 diabetes (such as Jardiance, Basaglar) needed to co-create the product. Example: time-action profiles of medications, common challenges and unmet needs.
- access to the network and the market.
Business model that we consider: freemium for end users; B2B with reducing costs for insurance companies and healthcare providers; B2B/licensing with providing additional value to existing offerings.
Market adoption: this is the point where collaboration with BI is crucial.
Here's an example of collaboration: BI has in its product portfolio a long-acting insulin Basaglar (insulin glargine biosimilar), recently approved in the United Stated. DiabetesLab could enhance this offering with an app which would help to calculate optimal dosing and timing of the doses. Calculations can be based on patients' data and specifics of this particular insulin.
I’d like to implement together, other (Please explain below).
I’d like to design together
Healthcare providers, insurance companies and pharmacies – access to the market/distribution of the solution, so that it would reach the end users.